Inmolecule Nanotech, S.A.
MLINA | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- ES0105908000
- LEI:
- 959800F0D3TQYVTXW034
- Country:
- Spain
- Address:
- N/A
- Website:
- https://www.inmolecule.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inmolecule Nanotech, S.A. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Inmolecule Nanotech, S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inmolecule Nanotech, S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Clinical research for dermatological testing in cosmetics, pharma, and health food sectors.
South Korea
347740
South Korea
347740
Developing high-yield, resilient crops via gene discovery for global seed companies.
Israel
PLNT
Israel
PLNT
Developing novel integrin-based therapies for fibrosis and related diseases.
United States of America
PLRX
United States of America
PLRX
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG
Poland
PTG
Develops drugs for metabolic diseases, including NASH, rare diseases, and an approved diabetes drug.
France
POXEL
France
POXEL
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL
United States of America
DTIL
AI platform uses a vast tumor biobank to predict drug response and accelerate oncology discovery.
United States of America
POAI
United States of America
POAI
Distributes diagnostic imaging systems and develops proprietary digital health platforms.
Italy
PRE
Italy
PRE
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
United States of America
PMN
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
United States of America
PPCB